HH-120 nasal spray 1
PreclinicalSmall molecule
HH-120 nasal spray 1 is one of 3 small molecule programs targeting SARS CoV 2 Infection. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in SARS Cov 2 Infection
#DrugCompanyPhaseTrials
1Ibuzatrelvir
PfizerPhase 3
HH-120 nasal spray 1
BBeijing Ditan Hospital
Preclinical
Stool Simple
HHospices Civils de Lyon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
SARS CoV 2 Infection1 trial
A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Contacts of Individuals Infected With SARS-CoV-2
Completed·—·N/A·NCT05765279·281 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HH-120 nasal spray 1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- BBeijing Ditan Hospital